Get started
Author

Margarita Majem Tarruella

Observed names: M Majem Tarruella, M. Majem Tarruella, M.M. Tarruella
OpenAlex ID: A5026793094
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
2018 · Michele Maio, Michele Maio, et al. · The Lancet Oncology · 216
First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study
2010 · M.L. García de Paredes, F. del Moral González, et al. · Annals of Oncology · 89
LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
2022 · M. Tsuboi, Y-L. Wu, et al. · Annals of Oncology · 23
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
2024 · Ainara Soria Rivas, Yolanda Escobar Álvarez, et al. · Clinical & Translational Oncology · 21
Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
2017 · T. Mitsudomi, M.-J. Ahn, et al. · Annals of Oncology · 17
Management of Sinonasal Mucosal Melanomas and Comparison of Classification Staging Systems
2015 · Juan R. Gras-Cabrerizo, Xavier León-Vintró, et al. · American Journal of Rhinology and Allergy · 16
LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
2020 · J. Baena Espinar, V. Torri, et al. · Annals of Oncology · 14
PDF
1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain
2022 · M.R. Garcia Campelo, M. Domine Gomez, et al. · Annals of Oncology · 12
1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)
2020 · B.Y. Shim, S. Lee, et al. · Annals of Oncology · 8
PDF
LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
2022 · J. Remon Masip, B. Besse, et al. · Annals of Oncology · 7
PDF
508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
2023 · L. Paz-Ares, M-J. Ahn, et al. · Annals of Oncology · 5
PDF
989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)
2022 · M. Awad, G. Pelizzari, et al. · Annals of Oncology · 5
PDF
160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I
2021 · S. Ponce Aix, E. Carcereny Costa, et al. · Annals of Oncology · 5
PDF
Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
2019 · J Mosquera Martinez, M. Riuvadets, et al. · Annals of Oncology · 5
LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA
2022 · T. John, C. Grohe, et al. · Annals of Oncology · 4
1532P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results
2022 · D. Isla, E. Arriola, et al. · Annals of Oncology · 4
1317P Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
2020 · R. Blanco, E. Nadal, et al. · Annals of Oncology · 4
P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study
2023 · R. García-Campelo, M. Dómine Gómez, et al. · Journal of Thoracic Oncology · 3
PDF
157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy
2022 · M. Casarrubios, A. Cruz-Bermudez, et al. · Annals of Oncology · 3
1118P Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients
2020 · A. García-Castaño, I. González-Barrallo, et al. · Annals of Oncology · 3
PDF
Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
2019 · R. Laza-Briviesca, A. Cruz-Bermudez, et al. · Annals of Oncology · 3
10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
2023 · J. Remon Masip, B. Besse, et al. · Journal of Thoracic Oncology · 2
PDF
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
2022 · Solange Peters, Igor Letovanec, et al. · Lung Cancer · 2
PDF
Works count: 68
Citation count: 3,455
H-index: 10
I10-index: 10
Year
Topic
Type